PI3K in Retinal Angiogenesis 36. Jia S, Roberts TM, Zhao JJ (2009) Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21(2): 199–208. 37. Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111(3): 293–303. 38. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7): 1261–74. 39. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A (2009) Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res 69(3): 1027–36. 40. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, et al. (2008) Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453(7195): 662–6. 41. Garlich JR, De P, Dey N, Su JD, Peng X, et al. (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68(1): 206–15. PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7867